The influence of quercetin on the functional state of platelets and the viscosity of blood among the aged people with the metabolic syndrome
Abstract. The purpose of this research was to study the effect of quercetin on the functional state of platelets and blood viscosity among the aged patients with the metabolic syndrome (MS). 110 patients with MS in the age of 60-75 years were divided equally into the main and control groups. The patients of the main group received quercetin for 3 months (drug "Quertin", chewable tablets produced by private joint stock company scientific-productional centre "Borschagovsky chemical pharmaceutical plant") in dose 80 mg 3 times per day. The examined subjects from the control group were treated with placebo for the same time. Before and after the course of treatment, MS criteria were evaluated, platelet aggregation capacity, blood viscosity, and serum lipid levels were determined. After course treatment with quercetin, the rheological properties of blood were improved: its viscosity, spontaneous and induced aggregation of the platelets were decreased. A statistically significant decrease of total cholesterol and low density lipoprotein (LDL) cholesterol in serum was observed. Correlation analysis showed that the improvement of blood viscosity was due to the favorable changes in the lipid spectrum and a decrease of the aggregation capacity of platelets. Thus, the obtained results indicate that the use of course of quercetin by the aged patients with metabolic syndrome (within 3 months) reduces the manifestation of dyslipidemia, increased spontaneous and induced platelet aggregation, contributes to the increase of erythrocyte deformity index that together lead to a decrease of blood viscosity as one of the risk factors for complications of metabolic syndrome.
Anisimov, V.N. Molekulyarnyye i fiziologicheskiye mekhanizmy stareniya [Molecular and physiological mechanisms of aging (in Russian) ]. Nauka: St. Petersburg, 2003; p 468. doi: 10.1023/B:HUMP.0000042625.810.55
Berkovsky, A.L. Posobiye po izucheniyu adgezivno–agregatsionnoy aktivnosti trombotsitov (uchebnoye posobiye) [A manual on the study of adhesive aggregation activity of platelets (educational manual) (in Russian)]. Berkovsky, A.L.; Vasiliev, S.A.; Zherdeva, L.V., Ed. Мoscow, 2002; p 62.
Volkov, V.I. Trombotsitarnyy gemostaz i aterogenez: patogeneticheskiye i terapevticheskiye aspekty [The platelet hemostasis and atherogenesis: pathogenetic and therapeutic aspects]. Volkov, V.I.; Zaprovalnaya, O.E., Ed. Circulation and hemostasis (in Ukraine) 2003, 1, 18-25.
Korkushko, O.V.; Shatilo, V.B.; Ishchuk, V.A. et al. Insulinorezistentnost' kak faktor uskorennogo stareniya organizma [Insulin resistance as a factor of accelerated aging of the organism]. Problems of aging and longevity (in Russian) 2012, 21, 3, 357-367.
Korkushko, O.V.; Lishnevskaya, V.Y.; Duzhak, G.V. Reologicheskiye svoystva krovi pri starenii i faktory, ikh opredelyayushchiye [Rheological properties of blood during aging, and their determinants]. Circulation and hemostasis (in Ukraine) 2007, 1, 5-14.
Parkhomenko, A.N. & Kozhuhov, S.N. Novyye vozmozhnosti v lechenii bol'nykh s ostrym infarktom miokarda s elevatsiyey segmenta ST: korvitin dlya in"yektsiy [New possibilities in the treatment of patients with acute myocardial infarction with elevated segment of ST: corythrin for injections]. Ukr. Med. Journal (in Russian) 2004, 2, 40, 33-37.
Shilov, A.M. & Melnyk, M.V. Arterial'naya gipertoniya i reologicheskiye svoystva krovi [Arterial hypertension and rheological properties of blood (in Russian)]. "BARS": Мoscow, 2005; p 206.
Arts, I.C.; Hollman, P.C. Polyphenols and disease risk in epidemiologic studies. Am. J. Clin. Nutr 2005, 81, 1, 317S-325.
Babik, B.; Peták, F.; Agócs, S. et al. Diabetes mellitus: endothelial dysfunction and changes in hemostasis. Or. Hetil. 2018, 159, 33, 1335-1345.
Eto, K.; Ochiai, M.; Isshiki, T., et al. Platelet aggregability under shear is enhanced in patients with unstable angina pectoris who developed acute myocardial infarction. Jpn. Circ. J. 2001, 65, 279–282. doi: 10.1253/jcj.65.279
Ginsberg, H. N. & MacCallum, P. R. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J. Cardiometab. Syndr. 2009, 4, 2, 113-119. doi:10.1111/j1559-4572.2008.00044.x
Lemkes, B.A.; Hermanides, J.; Devries, J.H. et al. Hyperglycemia: a prothrombotic factor? J. Thromb. Haemost 2010, 8, 8, 1663-9.
Meigs, J.B.; Mittleman, M.A.; Nathan, D.M. et ai. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000, 283, 221–228. doi: 10.1001/jama.283.2.221
Middleton, E. & Kandaswami, C. The Effects of Plant Flavonoids on Mammalian Cells: Implications for Inflammation, Heart Disease, and Cancer. Pharmacol. Rev. 2000, 52, 4, 673-751.
Tang, L.Q.; Wei, W.; Chen, L.M.; Liu, S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J. Ethnopharmacol. 2006, 108, 1, 109-115. doi: 10.1016/j.jep.2006.04.019
Williamson, R.; McNeilly, A.; Sutherland, C. Insulin resistance in the brain: An old-age or new-age problem? Biochem Pharmacol 2012, 84, 6, 737-45. doi: 10.1016/j.bcp.2012.05.007
Wilson, P.W.; D'Agostino, R.B.; Parise, H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112, 20, 3066–3072. doi: 10.1161/CIRCULATIONAHA.105.539528